Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.57% | -3.98% | -5.77% | 1.19% | -0.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.57% | -3.98% | -5.77% | 1.19% | -0.55% |
| Cost of Revenue | -11.84% | -11.85% | -8.21% | 0.33% | 3.86% |
| Gross Profit | 462.34% | 177.97% | 48.43% | 17.17% | -270.95% |
| SG&A Expenses | -8.86% | -7.83% | -9.39% | -9.78% | -12.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.54% | -10.11% | -8.73% | -4.32% | -3.95% |
| Operating Income | 24.06% | 17.33% | 12.02% | 10.17% | 7.79% |
| Income Before Tax | -156.66% | -42.94% | -37.86% | 57.19% | 46.51% |
| Income Tax Expenses | -24.56% | -99.66% | -101.79% | -93.53% | -82.35% |
| Earnings from Continuing Operations | -156.52% | -42.46% | -37.43% | 57.27% | 46.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.52% | -42.46% | -37.43% | 57.27% | 46.60% |
| EBIT | 24.06% | 17.33% | 12.02% | 10.17% | 7.79% |
| EBITDA | 24.09% | 17.39% | 12.04% | 10.20% | 7.68% |
| EPS Basic | -77.08% | -30.34% | -23.13% | 56.42% | 50.04% |
| Normalized Basic EPS | 12.19% | 12.80% | 16.05% | 32.55% | 20.24% |
| EPS Diluted | -13.69% | 11.20% | 14.57% | 28.24% | 22.45% |
| Normalized Diluted EPS | 8.79% | 9.79% | 13.27% | 35.47% | 23.22% |
| Average Basic Shares Outstanding | 34.36% | 7.54% | 8.93% | 8.75% | 6.69% |
| Average Diluted Shares Outstanding | 25.75% | 0.50% | 1.64% | 16.02% | 14.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |